Safety Profile and Clinical and Virological Outcomes of Nirmatrelvir-Ritonavir Treatment in Patients With Advanced Chronic Kidney Disease and Coronavirus Disease 2019 (COVID-19).
Gordon Chun Kau ChanGrace Chung Yan LuiCandy Ngai Sze WongSindy Sin Ting YipTimothy Chun Man LiCatherine Siu King CheungRyan Kin Ho SzeCheuk Chun SzetoKai-Ming ChowPublished in: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2023)
Among patients with CKD, a modified dose of nirmatrelvir-ritonavir is a well-tolerated therapy in mild COVID-19 as it can effectively suppress the SARS-CoV-2 viral load with a favorable safety profile. Virological and symptomatic rebound, although transient with low infectivity, may occur after treatment. Nirmatrelvir-ritonavir should be considered for use in patients with CKD, including stage 5 CKD on dialysis. Clinical Trials Registration. Clinical Trials.gov; identifier: NCT05624840.
Keyphrases
- chronic kidney disease
- coronavirus disease
- sars cov
- antiretroviral therapy
- clinical trial
- end stage renal disease
- respiratory syndrome coronavirus
- hiv infected
- hiv infected patients
- phase ii
- open label
- skeletal muscle
- study protocol
- randomized controlled trial
- double blind
- phase iii
- combination therapy
- cell therapy
- replacement therapy
- weight loss
- bone marrow
- glycemic control
- blood brain barrier
- subarachnoid hemorrhage